AMP Therapeutics, a Germany-based spin-off company from professor Ralf Hoffmann’s laboratory at the University of Leipzig, has raised an undisclosed amount in its series A round from two healthcare companies’ corporate venturing units, Boehringer Ingelheim Venture Fund and Novartis Venture Funds.
Henry Skinner, managing director of Novartis Venture Funds, has joined AMP’s board and said: “AMP’s antibiotic therapies have significant potential to address serious Gram-negative infections caused by multi-drug resistant bacteria.”
Martin Heidecker, director at Boehringer Ingelheim Venture Fund, added: “We are pleased to join this project and look forward to working with the company as it continues to test and develop its lead compounds [targeting drug-resistant pneumonia, bloodstream infections, surgical site infections and urinary tract infections].”